GlassScriptPhysician profile
Alice L Yun
NPI 1831190099
$3,238.83
in general payments reported to CMS, 2019-2025
25 companies · $460 in 2025
The $460 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $518 · 2021: $634 · 2022: $483 · 2023: $383 · 2024: $392 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.36 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $219.90 | 2021-2024 | Veozah, Myrbetriq |
| Sage Therapeutics, LLC | $218.66 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $204.20 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $178.73 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $148.14 | 2019-2024 | Gardasil 9, Gardasil |
| Allergan, INC. | $142.99 | 2019-2020 | |
| Exeltis, USA INC. | $139.46 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $134.96 | 2019-2022 | |
| Pfizer INC. | $106.03 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.26 | 2019-2024 | |
| Lupin INC. | $89.60 | 2019-2020 | |
| Millicent US INC | $76.33 | 2025 | Intrarosa, Femlyv, Femring |
| Amag Pharmaceuticals, INC. | $65.91 | 2019-2020 | |
| Hologic Sales and Service, LLC | $60.15 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $58.83 | 2021-2022 | |
| Exact Sciences Corporation | $45.14 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $40.21 | 2021-2024 | |
| Zyla Life Sciences, INC. | $37.69 | 2020 | |
| Evofem Biosciences, INC. | $34.93 | 2020-2021 | |
| Mycovia Pharmaceuticals, INC. | $34.08 | 2022-2023 | Vivjoa |
| Supernus Pharmaceuticals, INC. | $24.90 | 2025 | Qelbree |
| Coopersurgical, INC. | $18.22 | 2019 | |
| Boston Scientific Corporation | $13.26 | 2019 | |
| Duchesnay USA Incorporated | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Yun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.